Sorafenib/Regorafenib and Lapatinib Interact to kill CNS Tumor Cells

The present studies were to determine whether the multi‐kinase inhibitor sorafenib or its derivative regorafenib interacted with the ERBB1/ERBB2 inhibitor lapatinib to kill CNS tumor cells. In multiple CNS tumor cell types sorafenib and lapatinib interacted in a greater than additive fashion to cause tumor cell death. Tumor cells lacking PTEN, and anoikis or lapatinib resistant cells were as sensitive to the drug combination as cells expressing PTEN or parental cells, respectively. Similar data were obtained using regorafenib. Treatment of brain cancer cells with [sorafenib + lapatinib] enhanced radiation toxicity. The drug combination increased the numbers of LC3‐GFP vesicles; this correlated with a reduction in endogenous LC3II, and p62 and LAMP2 degradation. Knock down of Beclin1 or ATG5 significantly suppressed drug combination lethality. Expression of c‐FLIP‐s, BCL‐XL, or dominant negative caspase 9 reduced drug combination toxicity; knock down of FADD or CD95 was protective. Expression of both activated AKT and activated MEK1 or activated mTOR was required to strongly suppress drug combination lethality. As both lapatinib and sorafenib are FDA approved agents, our data argue for further determination as to whether lapatinib and sorafenib is a useful glioblastoma therapy. J. Cell. Physiol. 230: 131–139, 2015. © 2014 Wiley Periodicals, Inc.

[1]  D. M. Olive,et al.  A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR- and EGFRvIII-expressing tumors , 2014, Cancer biology & therapy.

[2]  J. Rigas,et al.  Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. , 2013, Cancer treatment reviews.

[3]  R. Wheelhouse,et al.  Glioblastoma Multiforme Therapy and Mechanisms of Resistance , 2013, Pharmaceuticals.

[4]  L. Deangelis,et al.  Glioblastoma and other malignant gliomas: a clinical review. , 2013, JAMA.

[5]  F. D. De Braud,et al.  Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens , 2013, Cancer biology & therapy.

[6]  P. Dent,et al.  Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy , 2013, Cancer biology & therapy.

[7]  A. Di Carlo,et al.  Effects of low concentrations of Regorafenib and Sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro , 2013, Journal of cellular physiology.

[8]  Peter Houghton,et al.  A Proposal Regarding Reporting of In Vitro Testing Results , 2013, Clinical Cancer Research.

[9]  Ivan Babic,et al.  De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. , 2013, Cancer discovery.

[10]  Tom Mikkelsen,et al.  A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma , 2013, Clinical Cancer Research.

[11]  P. Dent,et al.  Lapatinib and Obatoclax Kill Breast Cancer Cells through Reactive Oxygen Species-Dependent Endoplasmic Reticulum Stress , 2012, Molecular Pharmacology.

[12]  P. Dent,et al.  OSU-03012 interacts with lapatinib to kill brain cancer cells , 2012, Cancer biology & therapy.

[13]  S. Vandenberg,et al.  Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240 , 2012, Proceedings of the National Academy of Sciences.

[14]  S. Spiegel,et al.  Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling , 2012, Cancer biology & therapy.

[15]  M. Rudek,et al.  Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients , 2012, Investigational New Drugs.

[16]  P. Fisher,et al.  Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. , 2011, Cancer research.

[17]  A. Azzariti,et al.  EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. , 2011, Frontiers in bioscience.

[18]  D. Häussinger,et al.  Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells , 2010, Molecular Cancer Therapeutics.

[19]  M. McDevitt,et al.  A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias , 2010, Leukemia.

[20]  A. Thorburn,et al.  BCL-2 Family Inhibitors Enhance Histone Deacetylase Inhibitor and Sorafenib Lethality via Autophagy and Overcome Blockade of the Extrinsic Pathway to Facilitate Killing , 2009, Molecular Pharmacology.

[21]  P. Fisher,et al.  Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation , 2008, Cancer biology & therapy.

[22]  G. Pond,et al.  Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Dent,et al.  The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress , 2007, Molecular and Cellular Biology.

[24]  P. Fisher,et al.  Radiation-induced cell signaling: inside-out and outside-in , 2007, Molecular Cancer Therapeutics.

[25]  P. Dent,et al.  Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation* , 2005, Journal of Biological Chemistry.

[26]  H. Hirte,et al.  BAY 43-9006: early clinical data in patients with advanced solid malignancies. , 2002, Current pharmaceutical design.